Status and phase
Conditions
Treatments
About
This is a multicenter, randomized, controlled, double-blind, phase III study.
Full description
This is a multicenter, randomized, controlled, double-blind, phase III study assessing the efficacy and safety of Olanzapine plus fosaprepitant plus ondansetron and dexamethasone versus fosaprepitant plus ondansetron and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk multi-day chemotherapy. Eligible patients will be randomized to receive either olanzapine plus fosaprepitant standard antiemetic therapy or fosaprepitant standard antiemetic therapy in a 1:1 ratio.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria: (abbreviated)
Exclusion Criteria: (abbreviated)
Primary purpose
Allocation
Interventional model
Masking
352 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Li Zhang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal